Search results for "Metas"

showing 10 items of 1693 documents

2019

Basal cell carcinoma has a potential for early and late metastasis. Depending on the location of the primary site, the relevant lymphatic drainage routes have to be monitored. Regional lymph edema may be a first indicator for metastasizing disease.

Oncologymedicine.medical_specialtybusiness.industryRodent ulcerGeneral MedicineDisease030204 cardiovascular system & hematologymedicine.diseaseMetastasis03 medical and health sciences0302 clinical medicineLymphatic systemLymphedema030220 oncology & carcinogenesisInternal medicineLYMPH EDEMAMedicineBasal cell carcinomabusinessClinical Case Reports
researchProduct

OC-0284: First results of the French cohort ANABASE : treatment and outcome in non-metastatic anal cancer

2018

IF 4.942 (2017); International audience

Oncologymedicine.medical_specialtybusiness.industry[SDV.CAN]Life Sciences [q-bio]/Cancer02 engineering and technologyHematology021001 nanoscience & nanotechnologymedicine.diseaseOutcome (game theory)3. Good health[SDV.CAN] Life Sciences [q-bio]/CancerOncology[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieInternal medicineCohort0202 electrical engineering electronic engineering information engineeringmedicineNon metastaticAnal cancer020201 artificial intelligence & image processingRadiology Nuclear Medicine and imaging[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie0210 nano-technologybusiness
researchProduct

Patient Reported Outcome in metastatic breast cancer and platinum-resistant recurrent ovarian cancer treated with metronomic cyclophosphamide ± metho…

2021

Oncologymedicine.medical_specialtybusiness.industrymedicine.diseaseMetastatic breast cancerRecurrent Ovarian CancerInternal medicineMedicinePatient-reported outcomeMethotrexatebusinessMetronomic cyclophosphamidePlatinum resistantmedicine.drugSenologie - Zeitschrift für Mammadiagnostik und -therapie
researchProduct

A randomized study of tucatinib (ONT-380) vs. placebo in combination with capecitabine and trastuzumab in patients with pretreated HER2-pos. metastat…

2018

Oncologymedicine.medical_specialtybusiness.industrymedicine.diseasePlaceboMetastatic breast cancerlaw.inventionCapecitabine03 medical and health sciences0302 clinical medicineRandomized controlled triallawTrastuzumab030220 oncology & carcinogenesisInternal medicinemedicineIn patientbusiness030217 neurology & neurosurgerymedicine.drugGeburtshilfe und Frauenheilkunde
researchProduct

Incidence and survival in late liver metastases of colorectal cancer

2014

Background and Aims Data concerning the risk of long-term liver metastasis following surgery of colorectal cancer in the general population are scarce. The 10-year incidence and prognosis of metachronous liver metastases remain unknown. Methods Among 4584 patients resected for cure for colorectal cancer recorded in two French digestive population-based cancer registries between 1985 and 2000, 602 presented metastases including liver metastases. Results The cumulated incidence of liver metastasis was 15% at 5 years and 17% at 10 years, and was mainly related to stage at diagnosis. The 10-year cumulative incidence was 6% for stage I and 30% for stage III. The hazard ratio was 3.2 [2.4–4.3] fo…

Oncologymedicine.medical_specialtyeducation.field_of_studyHepatologyRelative survivalbusiness.industryColorectal cancerPopulationHazard ratioGastroenterologyCancermedicine.diseaseCancer registryMetastasisInternal medicineMedicineCumulative incidencebusinesseducationJournal of Gastroenterology and Hepatology
researchProduct

Gastric and Rectal Metastases from Malignant Melanoma Presenting with Hypochromic Anemia and Treated with Immunotherapy

2017

The authors present a case of an 80-year-old Caucasian male with multiple gastric and rectal metastases from malignant melanoma presenting with hypochromic anemia as the sole symptom of disease without evidence of cutaneous and ocular tumor localization. The patient had a medical history positive for malignant lentigo melanoma of the occipital region of the scalp and early stage laryngeal squamous cell carcinoma and prostatic carcinoma treated with radiation therapy. The authors make some considerations on intestinal involvement by metastatic melanoma and discuss the choice of not treating with endoscopic procedures the gastric metastatic lesions most likely responsible for the clinical sig…

Oncologymedicine.medical_specialtymedicine.medical_treatmentCase ReportIpilimumabPembrolizumablcsh:RC254-28203 medical and health sciences0302 clinical medicineInternal medicinemedicineCarcinomaMedical historyStage (cooking)business.industryMelanomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseDermatologyRadiation therapyHypochromic anemiaOncology030220 oncology & carcinogenesis030211 gastroenterology & hepatologybusinessmelanoma rectal metastases immunotherapymedicine.drugCase Reports in Oncological Medicine
researchProduct

Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A case report of a multimodal treatment for peritoneal metastases…

2020

Highlights • Integration of PIPAC to systemic chemotherapy can have good tolerance profile. • Repeated biopsies performed during PIPAC allowed therapy-response monitoring. • Analysis of biopsies performed during PIPAC allowed tailoring of chemotherapy. • Integration of PIPAC to systemic chemotherapy can permit good quality of life.

Oncologymedicine.medical_specialtymedicine.medical_treatmentCase ReportPancreatic ductal adenocarcinoma03 medical and health sciences0302 clinical medicinePharmacokineticsQuality of lifeInternal medicinemedicineMultimodal treatmentAdverse effectChemotherapyPressurized intraperitoneal aerosol chemotherapy (PIPAC)CarcinomatosisSystemic chemotherapybusiness.industryStandard treatmentfungifood and beveragesPeritoneal metastases030220 oncology & carcinogenesisDrug delivery030211 gastroenterology & hepatologySurgerybusinessInternational Journal of Surgery Case Reports
researchProduct

Harmful Interference of Detoxifying Diets and Nutraceuticals with Adherence to Abemaciclib in Advanced Estrogen Receptor-Positive, Human Epidermal Gr…

2021

Many cancer patients use integrative therapies with a combination of natural products and diets. In the Western world, integrative medicine is often not shared with oncologists even during antineoplastic treatments. This behavior stems from the unmet needs of cancer patients who may feel oncologists’ underestimation of their symptoms and spiritual aspects. This case report demonstrates the potential harm of inadequate diet and nutraceutical intake in a 68-year-old woman with metastatic estrogen receptor-positive, human epidermal growth factor receptor-2-negative breast cancer. Her care team recommended hormone therapy with abemaciclib plus fulvestrant. Her diarrhea started after 10 days of …

Oncologymedicine.medical_specialtymedicine.medical_treatmentEstrogen receptorCase ReportDiseaseBreast cancerInternal medicineEstrogen receptorMedicineRC254-282Fulvestrantbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancerMetastatic breast cancermedicine.diseaseMetastatic breast cancerAbemaciclibOncologyDetoxifying dietNutraceuticalsHormone therapyIntegrative medicinebusinessmedicine.drugCase Reports in Oncology
researchProduct

Population Pharmacokinetics of Palbociclib in aReal-World Situation

2021

Palbociclib is an oral cyclin-dependent kinase inhibitor that is used in combination with aromatase inhibitors in the treatment of postmenopausal women with metastatic breast cancer. Its metabolism profile is associated with an important interpatient variability. We performed a population pharmacokinetics study of palbociclib in women routinely followed in a cancer center. One hundred and fifty-one samples were analyzed. The sampling times after administration ranged from 0.9 to 75 h and the samples were taken between 1 and 21 days after the beginning of the palbociclib cycle. Palbociclib was determined using a validated mass spectrometry method. The best model that described the concentrat…

Oncologymedicine.medical_specialtypalbociclibPharmaceutical ScienceRenal functionlcsh:Medicinelcsh:RS1-441Population pharmacokineticsAbsorption (skin)Palbociclib030226 pharmacology & pharmacyArticlelcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicineLag timepopulation pharmacokineticsInternal medicineDrug Discoverymedicinereal-world situationDosingPostmenopausal womenbusiness.industrylcsh:Rmedicine.diseaseMetastatic breast cancer030220 oncology & carcinogenesisMolecular MedicinebusinessPharmaceuticals
researchProduct

Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention

2014

// Nicole M. Davis 1 , Melissa Sokolosky 1 , Kristin Stadelman 1 , Stephen L. Abrams 1 , Massimo Libra 2 , Saverio Candido 2 , Ferdinando Nicoletti 2 , Jerry Polesel 3 , Roberta Maestro 4 , Antonino D’Assoro 5 , Lyudmyla Drobot 6 , Dariusz Rakus 7 , Agnieszka Gizak 7 , Piotr Laidler 8 , Joanna Dulinska-Litewka 8 , Joerg Basecke 9 , Sanja Mijatovic 10 , Danijela Maksimovic-Ivanic 10 , Giuseppe Montalto 11,12 , Melchiorre Cervello 12 , Timothy L. Fitzgerald 13 , Zoya N. Demidenko 14 , Alberto M. Martelli 15 , Lucio Cocco 15 , Linda S. Steelman 1 and James A. McCubrey 1 1 Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University Greenville, NC 27858 USA 2 …

Oncologymedicine.medical_specialtytherapy resistanceClass I Phosphatidylinositol 3-Kinasesmedicine.medical_treatmentBreast NeoplasmsReviewBiologyMechanistic Target of Rapamycin Complex 1PI3KMetastasisTargeted therapyPhosphatidylinositol 3-KinasesBreast cancerTARGETED THERAPYInternal medicinemedicinePTENHumansTargeted Therapy Therapy Resistance Mutations PI3K mTOR rapamycinskin and connective tissue diseasesProtein kinase BneoplasmsPI3K/AKT/mTOR pathwayRoswell Park Cancer InstituterapamycinTOR Serine-Threonine KinasesMTORPTEN PhosphohydrolaseCancerTargeted TherapyTherapy Resistancemedicine.diseaseTargeted Therapy; Therapy Resistance; Mutations; PI3K; mTOR; rapamycin3. Good healthErbB ReceptorsGene Expression Regulation NeoplasticOncologyMultiprotein ComplexesCancer researchbiology.proteinFemaleReceptor Epidermal Growth FactormutationRAPAMYCINProto-Oncogene Proteins c-aktMutationsSignal Transduction
researchProduct